Turn Therapeutics
Turn Therapeutics, with a valuation of $123.6 million, is raising funds on StartEngine. It is a pharmaceutical and medical device company known for its flagship formula, Hexagen Wound Dressing. Turn Therapeutics’ formula targets dermatological ailments, including moderate to severe eczema and toenail fungus, and has FDA marketing approvals in advanced wound and dermatitis management. The company has also developed its PermaFusion technology by fusing oil and water-soluble active ingredients to revolutionize drug delivery and is backed by three FDA clearances. Bradley Burnam founded Turn Therapeutics in January 2015. The current crowdfunding campaign has a minimum target of $14,990.94 and a maximum target of $4.1 million. The campaign proceeds will be used for company employment, working capital, and research and development.
Investment Overview
Raised: $1,321,309
Deal Terms
Total Commitments ($USD)
- Platform
- StartEngine
- Start Date
- 10/23/2024
- Close Date
- 01/20/2025
$14,991
$4,073,698
$248
Equity - Common
Series A
RegCF
$9.18
$123,605,918
Company & Team
Company
- Year Founded
- 2015
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $13,300,000
- VC Backed?
- No
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.